Last reviewed · How we verify

NCT03621722: AMBIENT

AroMatherapy for Blood and Marrow Transplant PatIENTs (AMBIENT)

Completed NA Last updated 11 February 2020
What this trial tests

NA trial testing Elequil Aromatabs in Anxiety in 30 participants. Completed in 31 December 2019.

Timeline
27 February 2017
Primary endpoint
2 October 2019
31 December 2019

Quick facts

Lead sponsorHackensack Meridian Health
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment30
Start date27 February 2017
Primary completion2 October 2019
Estimated completion31 December 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Hackensack Meridian Health — full company profile →

Who can join

22 and older, any sex, with Anxiety or Nausea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is comparing the difference between the use of Elequil Aromatabs versus standard of care practice treatments on Blood Marrow Transplantation patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anxiety

Currently open trials in the same condition.

Other Hackensack Meridian Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03621722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing